Streetbeat News

Products Services

IMNN

IMUNON has announced the database lock for its Phase 2 OVATION 2 study, which evaluates the safety and efficacy of IMNN-001, a novel IL-12 immunotherapy, in advanced ovarian cancer. The treatment is administered alongside the standard of care as a first-line treatment.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:32 pm

XELA

Exela Technologies shares are trading higher after the company announced a $35 million contract for security breach remediation.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:32 pm

MTNB

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) successfully treated a patient with a severe fungal infection using its oral MAT2203 under its Compassionate/Expanded Use Access Program. The patient was discharged after six weeks of treatment.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:32 pm

BDRX

Biodexa Pharmaceuticals announced positive Phase 2 trial results for eRapa in treating Familial Adenomatous Polyposis, showing significant non-progression and reduction in polyp burden. These results will inform Phase 3 dosage. The findings were presented at the 2024 InSIGHT meeting.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:32 pm

BFRI

Biofrontera Inc. (NASDAQ:BFRI) has launched its FDA-approved RhodoLED XL lamp, designed for use with Ameluz® gel in photodynamic therapy for actinic keratoses. The company began commercial distribution on June 10, 2024.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:31 pm

XELA

Exela Technologies has announced a $35 million contract for security breach remediation.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:31 pm

NNE

NANO Nuclear has acquired the ALIP Technology intellectual property from physicist Carlos Maidana and plans to collaborate on further development. The company will provide $350K funding for a Phase III project, building on $1.37M DOE grants. ALIP Technology is crucial for NANO Nuclear's 'ODIN' microreactor and has potential for commercialization within a year.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:31 pm

LLY

Eli Lilly's tirzepatide injection, marketed as Zepbound in the U.S., has shown significant efficacy in treating moderate-to-severe obstructive sleep apnea (OSA) in obese patients, achieving primary and key secondary endpoints in phase 3 trials. The company has submitted tirzepatide for FDA approval for this indication, with a decision expected by the end of the year.

Portfolio Pulse from Vandana Singh

June 24, 2024 | 12:29 pm

BMY

QGEN

The FDA has granted accelerated approval to Bristol Myers Squibb's (NYSE:BMY) Krazati (adagrasib) in combination with cetuximab for treating KRASG12C-mutated colorectal cancer. This approval is based on the Phase 1/2 KRYSTAL-1 study, which showed a 34% objective response rate. Bristol Myers Squibb acquired adagrasib through a $5 billion deal with Mirati Therapeutics. The company also partnered with QIAGEN NV (NYSE:QGEN) to develop a companion diagnostic for Krazati.

Portfolio Pulse from Vandana Singh

June 24, 2024 | 12:26 pm

EDSA

Edesa Biotech shares are trading higher after BARDA selected the company's drug for a U.S. funded platform trial in general acute respiratory distress syndrome.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:24 pm